Aficamten (CK-3773274, CK-274) is a novel next-generation cardiac myosin inhibitor (IC50 =1.4 uM) for treatment of hypertrophic cardiomyopathy.
Aficamten (CK-274) provides a projected human half-life appropriate for once a day dosing, reaching steady state within two weeks, has no substantial CYP induction or inhibition in preclinical assessment and demonstrates a wide therapeutic window in vivo with a clear PK/PD relationship.
